Aug 05, 2025
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Jul 30, 2025
Immutep Quarterly Activities Report Q4 FY25
Jul 29, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Jul 28, 2025
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Jun 23, 2025
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
May 26, 2025
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15, 2025
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
May 05, 2025
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Apr 29, 2025
Immutep Quarterly Activities Report Q3 FY25
Mar 24, 2025
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Mar 19, 2025
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Jan 30, 2025
Immutep Quarterly Activities Report Q2 FY25
Jan 21, 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Jan 06, 2025
Patient Enrolment Completed for INSIGHT-003
Dec 16, 2024
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
